XOMA — XOMA Royalty Corporation Stock Price, Chart & AI Report

Negative May 14, 2026 • 17:51 UTC GlobeNewswire Inc. • Brodsky & Smith

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

VRE XOMA XOMAO XOMAP merger investigation fiduciary duty shareholder litigation fair value

Sentiment note

Under investigation for potential breach of fiduciary duties; deal price of $39.00/share is below 52-week high of $42.38, suggesting potentially undervalued transaction

Negative May 7, 2026 • 01:14 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

HLX OGN XOMA XOMAO merger investigation shareholder rights fiduciary duty securities law

Sentiment note

Under investigation for potential securities law violations in sale to Ligand Pharmaceuticals for $39.00 per share; questions raised about fairness of transaction terms

Negative Apr 28, 2026 • 21:40 UTC GlobeNewswire Inc. • Schall Law Firm

XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm

The Schall Law Firm is investigating potential breaches of fiduciary duty by XOMA Royalty Corporation's board and management regarding the company's $739 million acquisition by Ligand Pharmaceuticals. Shareholders are invited to participate in the investigation.

XOMA XOMAO XOMAP LGND fiduciary duty shareholder rights acquisition securities litigation

Sentiment note

The company is under investigation for potential breaches of fiduciary duty by its board and management, suggesting governance concerns and potential shareholder harm in the acquisition deal.

Negative Apr 28, 2026 • 01:23 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

OGN XOMA XOMAO XOMAP M&A investigation shareholder rights fiduciary duty securities law

Sentiment note

Under investigation for potential violations in $39.00 per share sale to Ligand Pharmaceuticals, raising concerns about fair dealing and shareholder protection

Positive Apr 27, 2026 • 17:18 UTC Benzinga • Vandana Singh

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million ($39.00 per share in cash). The deal is expected to be immediately accretive to adjusted EPS and increases Ligand's 2026 guidance to $8.50-$9.50 per share, with an additional $1.50 per share contribution expected in 2027. The acquisition expands Ligand's royalty portfolio and strengthens its position as a leading biopharma royalty aggregator.

LGND XOMA XOMAO XOMAP acquisition royalty portfolio EPS guidance biopharma

Sentiment note

Shareholders receive $39.00 per share in cash plus contingent value rights from pending litigation. Stock price up 9.23% at announcement, reflecting positive market reaction to the acquisition deal terms.

Negative Apr 27, 2026 • 14:58 UTC GlobeNewswire Inc. • Monteverde & Associates Pc

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of XOMA Royalty Corporation (NASDAQ: XOMA)

Monteverde & Associates PC announced investigations into multiple companies involved in M&A transactions, including XOMA Royalty Corporation's proposed sale to Ligand Pharmaceuticals at $39.00 per share in cash. The firm is examining whether the deal terms are fair to shareholders.

XOMA XOMAO XOMAP LGND M&A investigation class action shareholder lawsuit acquisition

Sentiment note

The company is under investigation by a class action firm regarding the fairness of its acquisition terms, suggesting potential shareholder concerns about whether the $39.00 per share offer adequately values the company.

Negative Apr 27, 2026 • 14:55 UTC GlobeNewswire Inc. • Juan Monteverde, Monteverde & Associates Pc

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Miluna Acquisition Corp. (NASDAQ: MMTX)

Monteverde & Associates PC, a class action securities firm, has announced investigations into Miluna Acquisition Corp. (MMTX) regarding its merger with CADV Ventures S.A., as well as investigations into XOMA Royalty Corporation (XOMA) and Helix Energy Solutions Group, Inc. (HLX). The firm is seeking shareholders with concerns about potential fairness issues in these transactions.

MMTX MMTXU MMTXW XOMA class action merger investigation shareholder alert M&A

Sentiment note

Company is subject to a class action investigation by Monteverde & Associates PC, indicating potential legal concerns affecting shareholders.

Positive Apr 27, 2026 • 11:00 UTC Benzinga • Na

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Ligand Pharmaceuticals announced it will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. The acquisition expands Ligand's royalty portfolio to over 200 assets and adds seven commercial products. Ligand raised its 2026 adjusted EPS guidance to $8.50-$9.50 and expects the transaction to be accretive by $1.50 per share in 2027. The deal is expected to close in Q3 2026.

LGND XOMA XOMAO XOMAP acquisition royalty aggregator biopharmaceutical portfolio expansion

Sentiment note

XOMA shareholders receive a 14% premium to the 30-day volume weighted average price at $39.00 per share, plus CVRs providing optionality from pending litigation. The acquisition provides liquidity and allows XOMA's portfolio to benefit from Ligand's business development capabilities and financial synergies.

Positive Mar 18, 2026 • 20:30 UTC Benzinga • Globe Newswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Corporation announced its Board of Directors has authorized quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary share holders will receive $0.52344 per depositary share. Dividends will be paid on or about April 15, 2026, to shareholders of record as of April 2, 2026.

XOMA XOMAO XOMAP preferred stock dividends Series A Cumulative Perpetual Preferred Stock Series B Cumulative Perpetual Preferred Stock biotechnology royalty aggregator dividend payment

Sentiment note

The company is maintaining its dividend payments to preferred shareholders, demonstrating financial stability and commitment to returning capital to investors. Regular dividend declarations are generally viewed positively as they indicate consistent cash generation and shareholder-friendly capital allocation.

Positive Mar 18, 2026 • 10:00 UTC GlobeNewswire Inc. • Na

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

DAWN ZVRA RZLT GOSS biotech royalty aggregator cash receipts portfolio expansion acquisitions

Sentiment note

Strong financial performance with 68% increase in royalties, positive operating cash flow, successful capital deployment through acquisitions and share buybacks, and multiple near-term catalysts expected in 2026 including regulatory decisions and late-stage clinical readouts that could drive future revenue growth.

Positive Feb 9, 2026 • 14:53 UTC Benzinga • Globe Newswire

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

XOMA Royalty Corporation successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. for $4.2913 per share in cash plus one contingent value right. Approximately 70% of Generation Bio's outstanding shares were validly tendered by the February 6, 2026 expiration date, satisfying the minimum tender condition. Following the acquisition, Generation Bio became a wholly owned subsidiary of XOMA Royalty and ceased trading on Nasdaq.

XOMA XOMAO XOMAP GBIO tender offer acquisition biotechnology royalty aggregator

Sentiment note

Successfully completed a strategic acquisition of Generation Bio, expanding its portfolio and demonstrating execution capability. The acquisition adds Generation Bio's delivery platform to XOMA Royalty's biotechnology royalty aggregator business, which should enhance its asset base and future revenue potential.

Negative Jan 20, 2026 • 21:47 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital hyperinsulinism. XOMA's stock fell 22.76% on the news.

XOMA XOMAO XOMAP RZLT securities fraud class action lawsuit Phase 3 trial failure stock price decline

Sentiment note

Development partner's Phase 3 trial for key drug candidate failed to meet primary and secondary endpoints, resulting in a 22.76% stock price decline and triggering a securities fraud investigation by a major law firm.